Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancerJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHIF12.82024-11-200OAAI
Beyond the Canonical: uORF-encoded Micro Peptides as Novel Kinase Inhibitors in Cancer TherapyCANCER RESEARCHIF16.62024-04-150PRE
New insights into RAS in head and neck cancer头颈癌中RAS的新见解BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCERIF8.32023-11-014PRE
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancerMOLECULAR ONCOLOGYIF4.52023-08-318OA
Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategySCIENTIFIC REPORTSIF3.92023-07-247OAAI
Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-AnalysisFRONTIERS IN ONCOLOGYIF3.32022-05-0613OAAI
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancerJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-03-1523OAAI
Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCsPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12021-10-0533PRE
EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulationCANCER LETTERSIF10.12021-02-0127OAAI
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsCANCER DISCOVERYIF33.32021-01-0637OAAI
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancerINTERNATIONAL JOURNAL OF CANCERIF4.72019-02-1128OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向